Week In Review: UCB Sells China Drug Portfolio To CBC For $680 Million

UCB announced plans to divest its current China five-drug portfolio, narrowing its China focus to commercialize soon-to-arrive late-stage clinical assets. It will sell this “mature” neurology and allergy portfolio for $680 million to CBC Group.